Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
Woodcliff Lake, US
41 (est)+8%
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, US

Key People at Eagle Pharmaceuticals

Scott L. Tarriff

Scott L. Tarriff


Eagle Pharmaceuticals Locations

Woodcliff Lake, US

Eagle Pharmaceuticals Metrics

Eagle Pharmaceuticals Summary

Market capitalization

$1.02 B

Closing share price

Eagle Pharmaceuticals's current market capitalization is $1.02 B.

Eagle Pharmaceuticals Financials

Eagle Pharmaceuticals's revenue is $66.2 M in FY, 2015
FY, 2015


$66.2 M

Gross profit

$50.6 M

Operating income

$2.56 M

Operating expense total

$63.7 M

Net Income

$2.57 M

Operating cash flow

$44.2 M

    Eagle Pharmaceuticals Market Value History

    We estimate that Eagle Pharmaceuticals's current employees are approximately 35% female and 65% male.

    Eagle Pharmaceuticals Online Presence

    Eagle Pharmaceuticals News

    Eagle Pharmaceuticals Company Life

    You may also be interested in